Agios Pharmaceuticals Buyback Yield % Related Terms
Agios Pharmaceuticals Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Agios Pharmaceuticals's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8AP vs ABCL, KOD, IMNM: Buyback Yield % Comparison
For the Biotechnology subindustry, Agios Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agios Pharmaceuticals Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Agios Pharmaceuticals's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agios Pharmaceuticals (FRA:8AP) has a Buyback Yield % of 0.00 as of Jul. 05, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Agios Pharmaceuticals and its competitors. According to the industry distribution chart, Agios Pharmaceuticals ranks #999999 out of 741 companies in the Biotechnology industry.
Is Agios Pharmaceuticals' Buyback Yield % too high?
Agios Pharmaceuticals' current Buyback Yield % is 0.00. Based on the distribution chart, Agios Pharmaceuticals ranks #999999 out of 741 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Agios Pharmaceuticals has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Agios Pharmaceuticals' Buyback Yield % compare to ABCL and KOD?
According to the Biotechnology industry distribution chart, Agios Pharmaceuticals ranks #999999 out of 741 companies for Buyback Yield %. This places Agios Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Agios Pharmaceuticals and its competitors. Agios Pharmaceuticals's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agios Pharmaceuticals stock overvalued right now?
Agios Pharmaceuticals (FRA:8AP) has a current Buyback Yield % of 0.00. The stock's GF Value™ is €73.79, compared to a current price of €32.80 — trading 55.5% below its estimated fair value. The current Buyback Yield % is 0.00. Agios Pharmaceuticals' overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Agios Pharmaceuticals (FRA:8AP), the current Buyback Yield % is 0.00 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agios Pharmaceuticals (FRA:8AP) Overvalued in 2026?
Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued.
The current stock price of €32.80 is trading 55.5% below its estimated GF Value™ of €73.79.
Key valuation signals for FRA:8AP:
Buyback Yield %: 0.00
GF Value™: €73.79 vs. price of €32.80 (55.5% below fair value)
No single metric tells the full story. See the FRA:8AP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
44GF Score
Get the complete analysis for FRA:8AP
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8AP has been successfully added to your 
